The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Size Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market In 2026 And How Much Will It Reach By 2030?
The market size for isocitrate dehydrogenase (idh) inhibitors has seen substantial growth in recent years. It is anticipated to increase from $2.46 billion in 2025 to $3.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 26.8%. The expansion witnessed in previous periods can be attributed to developments in cancer genomics research, the existence of unmet oncology needs, innovations in mutation-driven drug discovery, the integration of these treatments within hospital oncology, and the enlargement of clinical trial initiatives.
The market size for isocitrate dehydrogenase (idh) inhibitors is anticipated to witness significant expansion in the upcoming years. It is projected to achieve a value of $8.02 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.6%. The expansion during the forecast period can be attributed to progress in precision medicine, biomarker-driven oncology treatments, rare cancer drug development pipelines, combination cancer therapies, and regulatory encouragement for targeted medications. Prominent trends for the forecast period include the broadening of targeted oncology treatments, increased development of drugs based on genetic mutations, a heightened focus on rare cancer therapy, greater utilization of precision oncology diagnostics, and developments in small molecule cancer inhibitors.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24577&type=smp
What Key Growth Drivers Are Influencing The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
The isocitrate dehydrogenase (IDH) inhibitors market is anticipated to expand, driven by the increasing incidence of acute myeloid leukemia. Acute myeloid leukemia (AML) is characterized as a rapidly progressing cancer of the blood and bone marrow, involving the swift production of abnormal white blood cells that hinder normal blood cell formation. The escalating frequency of acute myeloid leukemia is attributed to the growing aging population, as older individuals face a heightened risk of developing this aggressive blood cancer due to age-related changes in their bone marrow and immune system. Isocitrate dehydrogenase (IDH) inhibitors are utilized to treat acute myeloid leukemia by blocking mutant IDH enzymes, which helps restore normal blood cell development and decelerates the growth of leukemia cells. For example, a report released in February 2023 by the Australia-based non-profit organization, Leukaemia Foundation, predicted that from 2022 to 2035, over 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 are expected to be diagnosed with various blood cancers, primarily including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Consequently, the rising occurrence of acute myeloid leukemia is set to propel the growth of the isocitrate dehydrogenase (IDH) inhibitors market.
What Are The Core Segment Classifications In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
The isocitrate dehydrogenase (idh) inhibitors market covered in this report is segmented –
1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types
2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types
3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical
4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications
Subsegments:
1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma
2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)
3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers
Which Trends Are Supporting The Evolution Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
Leading companies in the isocitrate dehydrogenase (IDH) inhibitors market are prioritizing the attainment of regulatory approvals to broaden the clinical application of their treatments, expedite market entry, and establish a competitive edge in addressing IDH-mutant cancers. Regulatory approvals are official authorizations granted by health authorities, permitting a drug to be commercialized and utilized after its safety and effectiveness have been confirmed. For instance, in August 2024, Servier Laboratoires, a France-based pharmaceutical company, secured FDA approval for VORANIGO (vorasidenib) tablets as the first targeted therapy for patients with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. This oral treatment significantly improves progression-free survival, as demonstrated in the Phase 3 INDIGO trial, where patients achieved a median progression-free survival of 27.7 months compared to 11.1 months for the placebo group. VORANIGO provides a convenient and well-tolerated option with manageable side effects, marking a crucial advancement for a patient group that previously had limited treatment alternatives.
Which Companies Are Influencing The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
Major companies operating in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC
Access The Complete Isocitrate Dehydrogenase (IDH) Inhibitors Market Report:
Which Region Has The Strongest Presence In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (idh) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Isocitrate Dehydrogenase (IDH) Inhibitors Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24577&type=smp
Browse Through More Reports Similar to the Global Isocitrate Dehydrogenase (IDH) Inhibitors Market 2026, By The Business Research Company
Histone Deacetylase Inhibitors Market Report 2026
Metabolic Disorders Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report
Proton Pump Inhibitors Market Report 2026
https://www.thebusinessresearchcompany.com/report/proton-pump-inhibitors-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model